contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


medcap-ab-medcaps-business-area-specialty-pharma-acquires-xgx-pharma

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

MedCap är verksamt inom investeringsbranschen och fokuserar på långsiktiga ägarinvesteringar i medicinteknik- och läkemedelsföretag. Bolagets portfölj inkluderar företag inom sektorer som bioteknik och medicinteknik. Verksamheten är främst koncentrerad till Sverige, med en huvudsaklig närvaro i Stockholmsregionen. MedCap grundades 2001 och har sitt huvudkontor i Stockholm.

MedCap

MedCap's wholly owned subsidiary, Unimedic Pharma AB, has signed an agreement to acquire XGX Pharma ApS ("XGX") in Denmark. XGX is a fast-growing specialty pharma company with a pipeline of ...

MedCap's wholly owned subsidiary, Unimedic Pharma AB, has signed an agreement to acquire XGX Pharma ApS ("XGX") in Denmark. XGX is a fast-growing specialty pharma company with a pipeline of new products. Currently, XGX's has 7 products on the market, primarily in the Nordics. The pipeline consists of 20 niche products in either late-stage development or registration phase. Expected product launches for this pipeline will be during the coming years. XGX's net sales during the last 12 months amounted to 51m DKK, a growth of 91% compared to the same period previous year. The EBITDA margin for the last 12 months was 35%. The acquisition of XGX positions Unimedic as one of the leading Nordic specialty pharma companies with higher profitability, organic growth and a broad pipeline of niche products. Many of the pipeline products are also own products, which will offer good out-licensing opportunities outside the Nordic countries. Anders Larnholt, Head of Business Area Specialty Pharma and Chairman of Unimedic comments the acquisition: "With the addition of XGX, we can take the next step with Unimedic. We add scale in Unimedic's home markets and a pipeline that will offer strong growth opportunities. I'm especially impressed by both team's expertise and entrepreneurial mindset, and I look forward to what we can achieve together".Jens-Nikolaj Schøier, CEO of XGX, comments the transaction: "With this transaction, Unimedic recognizes all that has been created at XGX during the last 7+ years, and in particular the quality of key products and pipeline. We look forward to working closely together with Unimedic."The purchase price comprises an initial cash payment of 135 million DKK at closing for 100% of the company's shares, with a potential additional payment of up to 140 million DKK contingent upon the gross profit growth in 2025 and 2026. The acquisition is subject to FDI (Foreign Direct Investment) clearance in Denmark. If approved, the acquisition is expected to close during the third quarter of 2025.<div>This disclosure contains information that MedCap AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, on 25-06-2025 07:30 CET.</div>

MedCap AB: MedCap's Business Area Specialty Pharma Acquires XGX Pharma

USA:s Black Week ledde till överraskande inköp

Måste man arbeta långa dagar? Ekonomen funderar

Uppgångsvecka bakom oss, Tyskland gick vidare med sin megabudget

Finlands ekonomiska tillväxt: ”Varje dag och varje natt tänker jag på dig”

Nedgångsvecka bakom oss, AI-oron når även obligationsmarknaden